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ABSTRACT
THE VALIDITY OF POINT-OF-CARE GLUCOMETERS REFERENCED AGAINST THE
YSI 2300 STAT PLUS DURING AEROBIC ACTIVITY AND AN ORAL GLUCOSE
TOLERANCE TEST
Davoncie Granderson, M.S.Ed.
Department of Kinesiology and Physical Education
Northern Illinois University, 2018
Clayton Camic, Director

This thesis observes blood glucose and the dynamic changes that it undergoes within the
human body. Blood glucose is carbohydrate located within the blood which is used for providing
the body with energy in order to perform biological work. The level of carbohydrate in the blood
will change dynamically depending on various factors such as exercising and fasting. Blood
glucose is crucial to healthy metabolic function within the human body and it is important that it
be monitored, especially in the case of diabetes. Various methods of measurement are used for
reporting glucose levels ranging from the Yellow Spring Instruments 2300, the gold standard, to
handheld glucose monitors.
This thesis examines the dynamic nature of blood glucose using two separate protocols in
a laboratory study. The protocols being used allow for the examination of fasting, exercising and
post-prandial blood glucose levels in humans as well as the validity of the Nova Max Plus
handheld glucose monitor. Since glucose is required for the healthy functioning of the human
body, it is imperative that monitoring systems be validated in order to determine their efficacy.
Keywords: Blood glucose, blood glucose monitor, glucose kinetics, glycolysis, metabolism
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INTRODUCTION
Blood glucose is an important physiological variable in clinical and human performance
laboratories due to its relationship with various medical conditions and as an indicator of energy
availability to metabolically active tissue. For example, the measurement of blood glucose
following an overnight fast and oral glucose tolerance test are commonly used as screening and
diagnostic techniques for diabetes mellitus (American Diabetes Association, 2018). Specifically,
fasting blood glucose values of 100-125 mg·dL-1 are considered impaired or “prediabetic,”
whereas values >125 mg·dL-1 are classified as “diabetic” (American Diabetes Association,
2018). An oral glucose tolerance test (OGTT) involves the measurement of blood glucose
following the ingestion of a drink typically containing 75 grams of sugar (American Diabetes
Association, 2018). Blood glucose levels at the two-hour time point of 140-199 mg·dL-1 and
≥200 mg·dL-1 are classified as “prediabetic” and “diabetic,” respectively (American Diabetes
Association, 2018). In addition, blood glucose can be monitored during longer bouts of exercise
to provide information related to carbohydrate metabolism and as a preventative measure against
low blood sugar (i.e. hypoglycemia).
The maintenance of glucose in the blood is important for proper functioning of various
metabolic processes of the body and reflects the balance of carbohydrate intake, cellular uptake,
and glucose release by the liver (Angus et al., 2002; Coggan 1991; Coggan, 1997).
Hypoglycemia, or low blood sugar, is a state in which the energy demands of the body may not
be supplied, thereby leading to fatigue, decrements in mental acuity, and unconsciousness in
extreme cases (American Diabetes Association, 2018; Cryer, 2007;). The risk of hypoglycemia
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is of greatest concern to diabetics but can also play a factor in athletic performance during
intense or extensive exercise and be indicative of glycogen depletion (Cermak & van Loon,
2013). Thus, the measurement of blood glucose is critical for the health and safety of both
clinical and athletic individuals in home-, clinical-, or laboratory-based environments.
The reference techniques for measuring blood glucose typically involve using enzymatic
assays or isotope-dilution gas chromatography-mass spectrometry as suggested by the Centers
for Disease Control and Prevention (CDC; Hagvik, 2007). For example, the YSI 2300 STAT
PLUS (Yellow Springs Instruments, Ohio) analyzes blood glucose using the glucose oxidase
method and is considered the reference method by the U.S. Food and Drug Administration that
most other glucose meters are calibrated against (Ekhlaspour et al., 2017). Although the YSI
2300 STAT PLUS offers a high level of precision (±2% of the reading or 2.5 mg·dL-1; User’s
Manual YSI 2300 STAT PLUS), it requires complicated, expensive, and time-consuming
operation and maintenance procedures that are only realistic in laboratory and clinical settings.
In addition to these complications, the YSI 2300 is designed to be stationary and requires an
external energy source. Thus, for quick and easy blood glucose measurement in the field (e.g.
health fairs, schools, exercise facilities) or as a point-of-care test at home, the portable handheld
glucose monitors provide an attractive alternative over the more complex, laboratory-based
procedures.
These portable handheld glucose monitors are considered highly user-friendly (e.g.
simple to operate, small size, battery powered), cost-effective, and can produce results in
approximately 5 seconds from less than a drop of blood (i.e. 0.3 µL). Although measures of
quality control have been assessed in many handheld glucose monitors in the fasted state
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(Robinson & Sharp, 2012; Tack et al., 2012; Thomas et al., 2008) or in vitro (Bedini et al., 2016;
Ekhlaspour et al., 2017), there are limited data concerning these factors under dynamic
conditions of blood glucose. Therefore, the purpose of the present study was to examine the
validity and reliability of the Nova Max® Plus blood glucose monitoring system during an oral
glucose tolerance test and 60-minute bout of exercise.

METHODS
Subjects
A total of 30 subjects (mean age ± SD = 22.3 ± 1.9 yrs; body mass = 77.6 ± 14.2 kg;
height = 171.3 ± 9.6 cm; physical activity = 6.2 ± 4.3 hr·wk-1) were recruited to participate in a
single visit to the laboratory for the OGTT (n = 15) or 60-minute treadmill exercise test (n = 15).
In addition, the subjects did not report or exhibit any of the following that could significantly
affect the outcome of the study: (i) history of medical or surgical events, including
cardiovascular disease, heart disease, hypertension, diabetes mellitus, insulin resistance,
hypoglycemia, or any other metabolic, renal, hepatic, or musculoskeletal disorder; (ii) phobia to
needles or finger stick; (iii) fasting blood glucose level >100 mg·dL-1; (iv) any current physical
injury due to the physical demands and requirements of the study. Subjects recruited for the
OGTT (n = 15) were asked to avoid eating or drinking anything other than water for 8 hours
prior to their visit, whereas the subjects recruited to participate in the 60-minute treadmill
exercise (n = 15) were asked to avoid eating or drinking anything other than water for 2-3 hours
prior to their visit. The study was approved by the Northern Illinois University Institutional
Review Board, and all participants completed a health history questionnaire and signed a written
informed consent document prior to testing.
Procedures
Oral Glucose Tolerance Test (OGTT)
Fifteen subjects (mean age ± SD = 22.4 ± 1.7 yrs; body mass = 77.0 ± 13.2 kg; height =
170.5 ± 10.6 cm; physical activity = 5.0 ± 2.5 hr·wk-1) were tested in the morning following an
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8-hour overnight fast. Subjects had a baseline (0 min) blood glucose measurement taken
immediately prior to the ingestion of the glucose drink to ensure the subjects were in a fasted
state with normal levels of blood glucose (<100 mg·dL-1). If blood glucose levels were within
normal range, the subjects were asked to ingest a drink (296 mL) that consisted of 75 grams of
glucose (ThermoFisher Scientific, Waltham, MA). Subjects were then asked to sit quietly in the
laboratory with their blood glucose being measured at the 10, 20, 30, 60, and 90 minute time
points of the OGTT.
Treadmill Exercise
Fifteen subjects (mean age ± SD = 22.3 ± 2.2 yrs; body mass = 78.2 ± 15.6 kg; height =
172.2 ± 8.7 cm; physical activity = 7.3 ± 5.4 hr·wk-1) were tested for their blood glucose
responses during 60 minutes of walking on a treadmill (Woodway Desmo HP, Waukesha, WI).
Subjects had a baseline (0 min) blood glucose measurement taken immediately prior to the
treadmill test in which the subjects were asked to walk at 3.5 mph for a total of 60 minutes.
Blood glucose was measured at the 5, 10, 15, 30, and 60 minute time points of the test. At each
of these time points, the treadmill belt was paused to safely allow for the measurement of blood
glucose with the subject standing still. Following each measurement, the subject was instructed
to continue the test at 3.5 mph until the 60 minute time point had been reached.
Measurement of Blood Glucose
Blood glucose concentrations were measured from the fingertip at six different time
points during the oral glucose tolerance test (0, 10, 20, 30, 60, and 90 min) and treadmill test (0,
5, 10, 15, 30, and 60 min). The finger was cleaned with alcohol before the initial finger stick and
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prior to each blood sample. In addition, the initial blood drop that formed on the finger was
wiped away and the subsequent blood drops were sampled for analysis and used as the
representative blood glucose concentrations.
During the oral glucose tolerance tests and treadmill exercise tests, one blood sample was
analyzed four times at each time point, two by the YSI 2300 and two by the handheld device.
Specifically, 50 µL of whole capillary blood was collected at each time point using two
heparinized capillary tubes and transferred into a 1.5 mL graduated natural micro-centrifuge
tube. This sample was analyzed twice using the YSI 2300 and twice using the Nova Max Plus
using a micropipette to present the sample to the glucose monitor. The criterion reference
method of blood glucose analysis used in the present study was the Yellow Springs Instruments
(YSI) 2300 STAT PLUS Glucose and Lactate Analyzer (Yellow Springs, OH). In particular, the
YSI 2300 measures blood glucose from whole blood using the glucose oxidase method. This
technique required two 25 µL of whole blood collected into heparinized capillary tubes from a
finger stick. Duplicate YSI blood glucose results were required to be within ±4 mg·dL-1 to be
used for analysis and the average of these two measurements was used as the representative YSI
2300 value. The YSI 2300 whole blood glucose values were then converted to plasma
equivalents (whole blood * 1.12 = plasma), and this value was compared with the test strip
results of the handheld device (Nova Max® Plus; Nova Biomedical Corp., Waltham, MA). For
quality control, the YSI 2300 was calibrated against 180 and 900 mg·dL-1 solutions according to
the manufacturer’s guidelines (User’s Manual YSI 2300 STAT PLUS). The handheld device
required 0.3 µL of whole blood for the measurement of blood glucose within 20-600 mg·dL-1
using an electrochemical glucose oxidase biosensor. In addition, the handheld device was
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checked for accuracy against a known quality control solution prior to testing as recommended
by the manufacturer (Nova Biomedical Corp.).
Data Analysis
Data are provided as mean ±SD. Accuracy of the handheld glucose monitor compared to
the reference YSI 2300 values involved multiple analyses. First, mean differences in blood
glucose values between the YSI 2300 and handheld monitor across time during the OGTT and
exercise tests were assessed using separate two-way (Method x Time) analyses of variance
(ANOVAs) with repeated measures and follow-up paired-samples t- tests when appropriate.
Accuracy was also assessed through: 1) calculation of the mean absolute relative deviation
(MARD); 2) comparing test results of the handheld monitor against the ISO 15197:2013
performance standards (International Organization for Standardization); 3) simple linear
regression from the calculation of constant error (CE = mean difference for YSI blood glucose –
handheld blood glucose), Pearson correlation coefficient (r), and standard error of estimate
(SEE = SD√1 − r 2 ); and 4) Bland-Altman (1986, 2010) analyses. Intra-device reliability for
the handheld glucose meter was assessed using coefficient of variation (CV), intra-class
correlation coefficient (ICC), and paired-samples t- tests. An alpha of 0.05 was used for
statistical significance.
Results
Accuracy. The results of the two-way repeated-measures ANOVA for blood glucose values
during the OGTT indicated there was a significant (p < 0.05) Method x Time interaction [F(5,70)
= 2.806, p = 0.023]. Follow-up paired-samples t- tests indicated that the handheld monitor
resulted in significantly greater blood glucose values than the YSI 2300 at each time point (Table

Table 1

Mean (±SD) Blood Glucose Values from the YSI 2300 and Nova Max Plus During an Oral Glucose Tolerance Test and Treadmill
Exercise.

YSI 2300 (mg·dL )

Oral glucose tolerance test time (minutes) (n = 15)
0
10
20
30
87.3 (±4.7)
116.0 (±10.4) 143.4 (±13.5) 158.5 (±16.6)

60
132.7 (±21.8)

90
113.5 (±12.7)

Nova Max Plus (mg·dL-1 )

97.3 (±8.0)*

130.9 (±12.6)*

141.5 (±22.3)*

120.2 (±15.2)*

0
86.1 (±9.9)

Treadmill exercise time (minutes) (n = 15)
5
10
15
84.6 (±9.5)
85.9 (±8.2)
85.3 (±7.2)

30
86.1 (±5.4)

60
87.6 (±6.0)

92.4 (±8.0)

90.7 (±7.5)

Method
-1

Method
-1

YSI 2300 (mg·dL )

Nova Max Plus (mg·dL-1 )† 91.8 (±9.2)

90.6 (±8.1)

157.7 (±17.4)*

89.9 (±8.0)

170.9 (±19.7)*

90.7 (±8.5)

*Significantly (p < 0.05) greater than YSI 2300 blood glucose value.
†Main effect (p < 0.05) for method (Nova Max Plus > YSI 2300) collapsed across time.
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1). For blood glucose values during the treadmill exercise test, there was no significant Method x
Time interaction [F(5,70) = 0.868, p = 0.507] or main effect for time [F(5,70) = 0.533, p =
0.751], but there was a main effect for method [F(1,14) = 12.191, p = 0.004]. A follow-up
paired-samples t- test indicated that the handheld monitor (86.2 ± 18.8 mg·dL-1) resulted in
significantly greater blood glucose values than the YSI 2300 (81.3 ± 19.8 mg·dL-1; collapsed
across time; Table 1). The MARD (±SD) and accuracy values for the Nova Max Plus compared
to the reference YSI 2300 method are provided in Table 2. Specifically, the overall MARD ±SD
was 9.0 ±7.0% and the combined blood glucose values (OGTT and treadmill exercise tests, n =
180) that were within the ISO 15197 criteria was 87.2% (157/180; Table 2).

Table 2

Accuracy of Nova Max Plus in Different Reference Blood Glucose Ranges.

MARD ± SD (%)
95% CI

Overall
9.0 ± 7.0
8.0 to 10.1

<100 mg∙dL-1
9.0 ± 7.3
7.6 to 10.4

>100 mg∙dL-1
9.1 ± 6.6
7.6 to 10.6

Values within
±5%/5 mg∙dL-1

80/180 (44.4%)

53/105 (51.5%)

27/75 (36.0%)

-1

149/180 (82.8%)

76/105 (72.4%)

43/75 (57.3%)

-1

157/180 (87.2%)

92/105 (87.6%)

65/75 (86.7%)

No

No

No

±10%/10 mg∙dL
±15%/15 mg∙dL

ISO standards* met?

*ISO 15197:2013 standards require that 95% of values <100 mg∙dL-1 be within
±15 mg∙dL-1 of reference value and 95% of values >100 mg∙dL-1 be within ±15%.
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The regression analyses of the Nova Max Plus versus the YSI 2300 reference method
during the OGTT, treadmill exercise, and overall combined (OGTT and treadmill exercise)
resulted in significant correlations (r = 0.95, 0.57, and 0.96), SEE values (8.7, 6.3, and 7.8
mg·dL-1), and CE values (11.2, 5.1, and 8.2 mg·dL-1; Table 3).

Table 3

Regression Analyses of the Nova Max Plus Versus the YSI 2300 Reference Method During an
Oral Glucose Tolerance Test and 60 Minutes of Treadmill Exercise.

OGTT (n = 15)

slope
0.88*

intercept
5.65

95% CIs
slope
intercept
0.81 to 0.94 -3.13 to 14.43

r
0.95

SEE
8.7

CE
11.2

Exercise (n = 15) 0.55*

35.72

0.39 to 0.72

20.50 to 50.95 0.57

6.3

5.1

All (n = 30)

7.81

0.82 to 0.90

3.47 to 12.15

7.8

8.2

0.86*

0.96

*Significantly (p < 0.05) greater than zero.
OGTT = oral glucose tolerance test.
SEE = standard error of estimate.
CE = constant error.

The Bland-Altman plot indicated there was a significant (p < 0.05) negative relationship
(r = -0.23) for CE (YSI 2300 – Nova Max Plus) versus the reference method (YSI 2300) as well
as negative bias (CE = -8.15 mg·dL-1; Figure 1).

Figure 1.

The relationship between constant error (YSI 2300 – Nova Max Plus) and the YSI 2300 blood glucose reference values
(n = 180; 30 subjects x 6 time points = 180). Dashed line represents the regression line.
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Reliability. Test-retest intra-device reliability analyses for the Nova Max Plus during the OGTT
and treadmill exercise test indicated there was no significant (p > 0.05) mean difference between
measurement 1 (113.9 ± 31.2 mg·dL-1) and measurement 2 (113.6 ± 31.4 mg·dL-1) on the
combined data (n = 180). The ICC and CV associated with measurement 1 versus measurement
2 were R = 0.99 and 3.0%, respectively. In addition, the relationship between measurement 1
and measurement 2 from the Nova Max Plus resulted in a significant correlation (r = 0.99; Figure
2).

Figure 2.

Test-retest reliability for the Nova Max Plus (n = 180; 30 subjects x 6 time
points= 180).
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Discussion
In the present investigation, the blood glucose responses during the OGTT and 60
minutes of treadmill exercise (Table 1) were comparable to those previously reported for healthy
individuals (Lui et al. 2008; Zinker et al. 1990). Specifically, the blood glucose values (mean
±SD) during the 75-g OGTT at the 0-min (87.3 ± 4.7 mg·dL-1) and 90-min (113.5 ± 12.7 mg·
dL-1) time points were below those associated with prediabetes (fasting: 100-125 mg·dL-1; 120min: 140-199 mg·dL-1) and diabetes (fasting: >125 mg·dL-1; 120-min: >200 mg·dL-1; American
Diabetes Association, 2018). In addition, the range in blood glucose values (84.6 ± 9.5 to 87.6 ±
6.0 mg·dL-1) during the treadmill test were similar to those of Zinker et al. (1990) over 60
minutes of moderate-intensity exercise. Thus, the subjects in the present study exhibited blood
glucose responses during the OGTT and 60-min exercise test that were consistent with healthy,
non-diabetic individuals of comparable age (Lui et al., 2008; Zinker et al., 1990).
Accuracy. The accuracy of the Nova Max Plus handheld monitor was assessed during two
dynamic conditions for blood glucose: an OGTT and 60 minutes of exercise. One of the main
findings of the present study was that the Nova Max Plus provided significantly greater blood
glucose values than the reference method (YSI 2300) under both conditions at all time points of
the tests (Table 1). Therefore, the Nova Max Plus consistently overestimated blood glucose
provided by the YSI 2300. In addition, the MARD and ISO 15197:2013 requirements were used
to examine the accuracy of the handheld monitor within different reference ranges of blood
glucose. Specifically, the calculation of MARD provides the mean absolute difference value
between the Nova Max Plus and reference method (YSI 2300) expressed as a percent of the
reference value (Obermaier et al., 2013). Thus, the MARD describes the magnitude of
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percentage bias of each measurement (Tack et al., 2012) and a lower MARD value is associated
with higher accuracy (i.e. closer to the reference value).
Although there are no set criteria for an “accurate” versus “inaccurate” MARD, values
ranging from 4.2 to 39.2 have been reported for multiple handheld units (Ekhlaspour et al. 2017;
Robinson & Sharp, 2012; Tack et al., 2012). Our results indicated that the Nova Max Plus
exhibited an overall MARD (±SD) of 9.0 (±7.0; n = 180) and values of 9.0 (±7.3) and 9.1 (±6.6)
at the low (<100 mg·dL-1, n = 105) and high (>100 mg·dL-1, n = 75) reference ranges of blood
glucose, respectively (Table 2). The overall MARD value of 9.0 was consistent with previous
findings for the Nova Max Plus under fasting conditions (MARD = 8.1; Robinson & Sharp,
2012) and in vitro preparations (MARD = 9.7; Ekhlaspour et al., 2017) that involved blood
samples modified for glucose (20-440 mg·dL-1). In addition, Ekhlaspour et al. (2017) reported
overall MARD (±SD) values ranging from 5.6 (±6.4) to 20.8 (±16.6) for 17 different handheld
blood glucose monitors versus the YSI 2300, with the Nova Max Plus ranking 8th for the lowest
MARD (9.7). Therefore, the findings of the present study and those of others (Ekhlaspour et al.,
2017; Robinson & Sharp, 2012) indicated that Nova Max Plus provides consistent MARD values
(9.0-9.7) within a wide range of blood glucose during fasting and dynamic conditions.
Although the present study was not conducted in vitro according to the strict compliance
guidelines of ISO 15197:2013 that require the manipulation of blood glucose and hematocrit,
their accuracy criteria was utilized in the evaluation of validity. The ISO 15197:2013 accuracy
requirements for blood glucose monitoring systems specify that 95% of the measured values be
within ±15 mg∙dL-1 of the reference for values <100 mg∙dL-1 and within ±15% for values >100
mg∙dL-1 (ISO 15197:2013). Overall, the Nova Max Plus did not meet the 95% accuracy criteria,
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yielding only 87.2% of readings within the required range (Table 2). To further examine the
accuracy of the Nova Max Plus, we determined the percentage of readings that fell within the
required range for values above and below 100 mg∙dL-1. In the reference range <100 mg∙dL-1,
the Nova Max Plus was only within ±15 mg∙dL-1 for 87.6% (92/105) of the values. For the
reference range >100 mg∙dL-1, only 86.7% (65/75) of the values were within the ISO 15197:2013
requirements of ±15%. The results of these analyses indicated that the Nova Max Plus does not
meet the ISO requirements in any of the three ranges (high, low, overall) of blood glucose that
we examined. These findings were consistent with previous studies that have examined Nova
Max Plus within fasting individuals and in vitro (Ekhlaspour et al., 2017; Robinson & Sharp,
2012) in which the Nova Max was found to have overall ISO 15197:2013 accuracy values of
89.0% and 88.2%, respectively.
Regression analyses were also completed to evaluate the prediction accuracy of the Nova
Max Plus versus the actual values of the reference YSI 2300. Tack et al. (2012) used regression
analyses in combination with MARD calculation to provide a comprehensive analysis of overall
accuracy in handheld monitors. Specifically, Tack et al. (2012) reported slope coefficients and r
values ranging from 0.98-1.04 and 0.97-0.99, respectively, for five different monitors. In the
present study, the Nova Max Plus exhibited a significant slope coefficient (0.86), correlation
coefficient (r = 0.96), and SEE value of ±7.8 mg∙dL-1 on the overall combined data from the
OGTT and exercise test (Table 3). The SEE value of ±7.8 mg∙dL-1 provided the average error
associated with predicting the reference YSI 2300 blood glucose value from the Nova Max Plus
and represented 4.9% and 9.2% of the highest (158.5 mg∙dL-1) and lowest (84.6 mg∙dL-1) mean
blood glucose values during OGTT and exercise test. More specifically, the Nova Max Plus and
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YSI 2300 readings during the OGTT trial resulted in a strong correlation (r = 0.95), whereas the
exercise trial resulted in a moderate correlation (r = 0.57). This discrepancy can be explained by
the lower range of blood glucose values during the 60-minute exercise test (84.6-87.6 mg∙dL-1)
compared to the OGTT (87.3-158.5 mg∙dL-1). In addition, the blood glucose values during
exercise did not significantly (p = 0.751) change across the 60-minute test. Although exercise
provides dynamic conditions in which glucose uptake by active skeletal muscle increases, this is
balanced by glucose release from the liver, thereby maintaining nearly constant blood glucose
values that change by less than 5 mg∙dL-1.
The relationship between CE (YSI 2300 – Nova Max Plus) and the reference (YSI 2300)
blood glucose values was analyzed using the method of Bland and Altman (1986; see Figure 1).
For this relationship, the mean CE was -8.15 mg·dL-1 and correlation coefficient was r = -0.23.
Constant error (CE) provides the mean difference between the actual (YSI 2300) and predicted
(Nova Max Plus) blood glucose values. Specifically, the negative CE of -8.15 mg·dL-1 indicated
that on average the Nova Max Plus overestimated the measurement of blood glucose by 8.15
mg·dL-1. In fact, 81% (145/180) of the blood glucose measurements from the Nova Max Plus
resulted in overestimated values. The negative correlation (r = -0.23) suggested that the absolute
CE values became greater at the high end of the reference (YSI 2300) blood glucose values.
Thus, the Nova Max Plus overestimated blood glucose values by approximately 8.15 mg·dL-1
and this error tended to increase at higher blood glucose values.
Reliability. Intra-device test-retest reliability analyses of the Nova Max Plus were performed on
the two blood glucose measurements taken at each time point during the OGTT and treadmill
test (30 subjects x 6 time points = 180 comparisons). As recommended by Atkinson and Nevill
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(1998), a number of statistical methods should be utilized for assessing reliability in variables
relevant to sports medicine to provide a comprehensive analysis. Our findings indicated there
were no significant mean differences between the first (113.9 ± 31.2 mg·dL-1) and second (113.6
± 31.4 mg·dL-1) measurements. Although suitable, the t-statistic does not provide an indication
of random variation between tests and should be interpreted with caution (Atkinson & Nevill
1998). Thus, we also utilized the ICC and CV as two additional statistical procedures that are
commonly used to assess relative and absolute reliability, respectively (McLain et al., 2015).
The ICC is used to describe the strength of the similarity of the values within a group, and
categories suggested by Vincent (1994) include “excellent” (R close to 1), “high” (R > 0.90),
“good” (R = 0.80-0.89), and “questionable” (R = 0.70-0.79). For CV, an acceptable boundary of
<10% has been previously proposed (Atkinson & Nevill 1998; McLain et al., 2015). Therefore,
the Nova Max Plus exhibited excellent relative reliability (ICC, R = 0.99) and acceptable
absolute reliability (CV = 3.0%). Collectively, these analyses indicated that the Nova Max Plus
provided highly reliability blood glucose values on two consecutive measurements taken at the
same time points during the OGTT and treadmill test.
In summary, the blood glucose values provided by the handheld Nova Max Plus were
significantly higher than those of the YSI2300 reference method at all time points of the OGTT
and 60-minute treadmill test. In addition, the Nova Max Plus exhibited an overall MARD (±SD)
of 9.0 (±7.0) and failed to meet the 95% accuracy requirements of ISO 15197:2013 (only 87.2%
of all values met the criteria). The YSI 2300 versus Nova Max Plus blood glucose relationships
resulted in a significant correlation (r = 0.96) and an SEE of ±7.8 mg·dL-1. The Bland-Altman
plot for CE (YSI 2300 – Nova Max Plus) versus the reference method (YSI 2300) indicated an
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average negative bias (CE = -8.2 mg·dL-1) that tended to increase (r = -0.23) at higher blood
glucose values. The intra-device reliability analyses of the Nova Max Plus, however,
demonstrated that the ICC was R = 0.99 and CV = 3.0%, with no significant mean differences
between test and retest values. These findings suggest that the Nova Max Plus provided highly
reliable, yet inaccurate blood glucose values compared to the YSI 2300 during the dynamic
conditions associated with an OGTT and exercise.

LITERATURE REVIEW
Carbohydrates are the preferred substrate from which the body yields adenosine
triphosphate (ATP) in order to fuel various processes. Glucose is a six-carbon sugar that may be
found within the blood readily available for the utilization of energy. Blood glucose comes from
two sources: foodstuffs that are consumed and from stored glucose in the form of glycogen in the
liver. The main source of blood glucose is food, namely foodstuffs with considerable amounts of
starch. The starches and sugars located within food are entered directly into the bloodstream as
glucose. The carbohydrates are first broken down into glucose by salivary and pancreatic
amylase and then absorbed through active transport (Wong & Jenkins, 2007). Other
carbohydrates, such as fructose and sucrose, are converted into glucose in either the small
intestine or liver. Excess glucose is synthesized into glycogen through the process of
glucogenesis and stored within the liver and muscles for later use.
Glucogenesis is a four-step process: (1) an ATP must provide a phosphate to the glucose
in order to form a glucose-6-phosphate through hexokinase, (2) the enzyme glucose-6-phosphate
isomerase isomerizes glucose-6-phosphate into glucose-1-phosphate, (3) the enzyme uridyl
transferase reacts uridine triphosphate (UTP) with the glucose-1-phosphate to create uridine
diphosphate-glucose and (4) the UDP-glucose attaches itself to a pre-existing glycogen polymer
chain (Bollen et al., 1998; Geddes, 1986; McGarry et al., 1987; Wilson, 2003). UTP is uridine
and three phosphates linked to the carbohydrate ribose (Leloir & Cardini, 1957). UTP acts as a
source of energy during metabolic reactions, and when UTP activates a substrate, a phosphate is
released and the remaining UDP binds with the substrate (Leloir & Cardini, 1957; Leloir &
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Goldemberg, 1960; Luck, 1961). This results in UDP-glucose in glucogenesis (Leloir & Cardini,
1957; Leloir & Goldemberg, 1960; Luck, 1961). In the case that there is a deficit of glucose in
the bloodstream, the liver will break down glycogen to glucose through the process of
glycogenolysis (König et al., 2012). Glycogen is made up of linkages of glucose; therefore, in
order to revert it back into glucose, the links must be broken (Wolfrom et al., 1951). Most
linkages are end-to-end while a few are cross, or side, linkages. The end-to-end linkages are
hydrolyzed by the enzyme phosphorylase while the cross-linkages are hydrolyzed by various
debranching enzymes (Wolfrom et al., 1951). These two processes work in tandem in order to
mobilize reserved glucose from the glycogen deposits. Glucose synthesis is not solely dependent
on glycogen stores because the body also possesses the ability to create glucose from noncarbohydrate substances such as amino acids, glycerol, lactate and pyruvate (Cori, 1931). This
process is referred to as gluconeogenesis and takes place in the liver just as glucogenesis and
glycogenolysis.
Where Does Glucose Go?
The body relies on glucose for the utilization of energy in most cases. Glucose goes to the
muscles that are in need of ATP. Glucose then goes through the process of glycolysis in which
ATP is formed from the sugar. Once ATP is synthesized from glucose it may be utilized to
perform biological work such as muscle contraction. Glycolysis is fundamentally the break down
of glucose into a usable form of energy (i.e. ATP) for the muscles and organs. Glycolysis may be
aerobic or anaerobic due to its ability to take place both in the presence and absence of oxygen.
Aerobic glycolysis yields larger amounts of ATP but takes considerably longer than anaerobic
glycolysis, which yields less ATP but at a greater rate. Both anaerobic and aerobic glycolysis
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produce pyruvate, which has the opportunity to be oxidized in the presence of ample oxygen or
reduced to lactate. Both anaerobic and aerobic glycolysis begin following the same general
pathway of events, starting with glucose. Throughout the cascade of events, enzymes react with
the six-carbon sugar in order to alter its composition, resulting in the phosphorylation of
adenosine diphosphate (ADP) into ATP that may be used by the body for energy. Energy is later
available as the ATP catabolizes into ADP and free energy.
At lower metabolic rates, resting muscle may oxidize lactate (Gladden, 2008). At higher
intensities requiring larger metabolic rates, however, the body fails to oxidize lactate due to the
oversaturation of CO2, or hypercapnia (Gladden, 2008; Jones, 1980). In anaerobic environments,
the final product of lactic acid will be without the oxygen needed to oxidize the hydrogen ions
associated with it due to the state of hypercapnia induced by high-intensity exercise (Gladden,
2008; Jones, 1980). This leads to lactic acidosis by way of accumulated hydrogen ions (H+)
which have dissociated from the lactate (Gladden, 2008; Jones, 1980). Increased glucose
utilization, such as during anaerobic exercise, is responsible for increasing H+ when oxygen
demand cannot be met (Jones, 1980). In the case of ample oxygen consumption to meet energy
requirements, the pyruvate created as a product of glucose catabolism in glycolysis will be able
to convert to acetyl-CoA (Jones, 1980; Krebs & Lowenstein, 1954) and continue to create ATP
by way of the citric acid cycle and electron transport chain (Krebs & Lowenstein, 1954). To
summarize, glucose is capable of producing ATP for the energy requirements of the body in both
highly oxidative and anaerobic environments (Gladden, 2008; Jones, 1980; Krebs & Lowenstein,
1954). If given the oxygen, the byproducts of glycolysis may continue to create increased
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amounts of ATP without the negative effects associated with the dissociation of H+ ions from
lactic acid accumulation (Krebs & Lowenstein, 1954).
Changes in Blood Glucose
The levels of glucose in any given body are not constant and the liver is constantly
working to maintain a homeostatic figure. Blood glucose levels change in relation to quite a few
factors. Factors such as fasting, consumption of food and exercise all maintain a specific blood
glucose level reaction within the body. Fasting blood glucose is defined as the level of glucose in
the blood of an individual who has not consumed food over an extended period of time (i.e. ≥8
hrs), such as when waking from sleep. Fasting blood glucose levels in healthy individuals
typically range from 70 to 100 mg∙dL-1 (American Diabetes Association, 2018). When the body
enters a fasted state, it will continue to use blood glucose for energy. As the amount of glucose in
the blood is not supplemented through eating, it will continue to drop. When blood glucose drops
below a specific value, insulin levels begin to fall as a protective measure, preventing further
uptake of glucose into the muscles and other tissues (Horwitz et al., 1975). When insulin is low
enough, the body will begin to create more glucose in order prevent hypoglycemia.
Glycogenolysis will become an active process in order to replenish blood glucose and return the
individual to homeostatic levels. In the case that glycogen stores are entirely depleted,
gluconeogenesis will allow for the conversion of amino acids and glycerol from triglycerides in
order to meet energy needs (Majumder et al., 2016).
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Digestion and glucose. Postprandial blood glucose is defined as the blood glucose
concentration following the consumption of food. It is important that individuals consume
glucose throughout the day because falling below 55-60 mg∙dL-1 is indicative of hypoglycemia
(Cryer et al., 2009). Glucose levels typically experience a change following consumption and
during digestion due to the carbohydrate within the food. Approximately 10 minutes after a
meal, the blood glucose levels will begin to rise due to the absorption of carbohydrates and
continue to rise for approximately an hour before peaking (American Diabetes Association,
2001). Postprandial blood glucose in healthy individuals will rarely exceed 140 mg∙dL-1 prior to
returning to pre-prandial blood glucose levels approximately two to three hours following their
meal. Glucose will increase after a meal and then continue to decrease to previous levels. This
pattern is typical and expected in healthy individuals due to postprandial insulin release.
Following a meal, peptides responsible for glucose homeostasis within the
gastrointestinal system are released. Glucose-dependent insulinotropic polypeptide and
glucagonlike peptide-1 stimulate the activation of insulin after the consumption of glucose
(Tseng et al., 1996). Insulin is the hormone responsible for allowing the uptake of glucose into
the various tissues of the body (Baron et al., 1988; Morgan et al., 1961). If blood glucose is
rising above normal level, insulin will be released in order to upregulate the absorption of
glucose into bodily tissue. The opposite happens in cases of fasting in which glucose levels drop
below normal levels as described above. In this case, insulin levels drop in order to allow what
little glucose that is present in the blood to remain. There are, however, cases in which
postprandial glucose concentrations do not follow the expected rise above and return to preprandial levels as described previously (Dunstan et al., 2012). Factors such as diet or insulin
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resistance may have an exaggerated effect on postprandial blood glucose. The repeated
consumption of meals high in calories and processed carbohydrates may lead to uncharacteristic
spikes in postprandial blood glucose concentrations (Dunstan et al., 2012). Due to the wavering
nature of blood glucose, it is important to monitor and report uncharacteristically high or low
levels in diabetics.
Exercise and glucose. As with fasting and postprandial measures, blood glucose levels
vary in response to differing exercise modalities and intensities (Ahlborg et al., 1974; Coggan et
al., 1995; Fujimoto et al., 2003; Zinker et al., 1990). Blood glucose levels are critical for exercise
because the body requires an increased amount of fuel in order to maintain the muscular activity.
Low levels of blood glucose and muscle glycogen are factors that contribute to fatigue in
exercising individuals (Hultman et al., 1991). Blood glucose levels increase at the onset of
exercise due to the increased requirement of energy, then begin to decline as the body continues
to use the glucose that is available (Foskett et al., 2008; Rose & Richter, 2005; Zinker et al.,
1990). After a peak in blood glucose measures, blood glucose will continue to drop until exercise
ceases (Foskett et al., 2008; Zinker et al., 1990). Though a decline in blood glucose is apparent, it
will typically remain within 10% of normal glucose values until exercise stops (Zinker et al.,
1990). The body maintains these blood glucose levels during exercise by way of hepatic glucose
release. One way that the body does so is by the increased release of glucose within the gut, liver
and kidneys into the blood during onset of exercise to compensate for the decreased levels
(Meyer, Dostou, et al., 2002; Meyer, Stumvoll, et al., 2002). The liver is also capable of
releasing glucosyl units that were stored in glycogen to stimulate gluconeogenesis in the liver
and kidneys using precursor molecules such as lactate (Meyer, Stumvoll, et al., 2002). During
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exercise, uptake of glucose within the muscles is largely increased in order to provide energy for
the activity being performed and this is why a decline in glucose values is observable (Rose &
Richter, 2005; Zinker et al., 1990).
The more muscles recruited for an activity, the larger the peripheral glucose uptake (Rose
& Richter, 2005). At rest, glucose uptake in peripheral muscles is minimal. At the onset of
exercise, glucose uptake within the involved muscles increases, which ultimately increases
whole-body glucose uptake (Kjaer et al., 1991). This explains the phenomena of blood glucose
levels dropping as exercise is maintained. Due to the nature of increased blood glucose uptake
within the body during exercise, it is important that the levels are monitored in order to prevent
hypoglycemia.
Importance of Measurement
The measurement of blood glucose in various conditions has both clinical and
performance implications. For example, diabetes mellitus is a disease characterized by
abnormally high blood glucose levels due to either insulin resistance or insulin dependence
(American Diabetes Association, 2018). Type II diabetes mellitus is an insulin-resistant
condition in which uptake of glucose into tissues is largely suppressed due to the inability to
efficiently use insulin (American Diabetes Association, 2018). Type I diabetes mellitus is an
insulin-dependent condition in which the pancreas creates little or no insulin, resulting in
decreased glucose uptake within the tissues (American Diabetes Association, 2018). Both of
these conditions result in a state of hyperglycemia, which is when blood glucose levels are well
above the normal healthy levels (American Diabetes Association, 2001).
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As stated previously, insulin is the hormone responsible for glucose uptake within the
muscles and other tissues of the body (Baron et al., 1988; Morgan et al., 1961). When insulin
availability is miniscule, or if the insulin available is not effective enough, the amount of glucose
allowed into bodily tissue is minimal, which leads to increased amounts of glucose in the blood,
or hyperglycemia. Chronically high levels of blood glucose associated with type II diabetes are
also related to an increased risk of various forms of heart disease (Cinar et al., 2001; Haffner &
Cassels, 2003; Kannel & McGee, 1979; Qazi & Malik, 2013). The Framingham Heart Study
(Mahmood, Levy, Vasan & Wang, 2014; Qazi & Malik, 2013) is an ongoing cardiovascular
cohort study in which various risks of cardiovascular disease are assessed and reported. One of
the first associations between cardiovascular disease and diabetes was made in 1979 with the aid
of this study (Kannel & McGee, 1979; Qazi & Malik, 2013). The mortality of cardiovascular
disease had been reported to be three times higher in individuals with diabetes due to increased
levels of heart failure and hypertensive heart disease (Kannel & McGee, 1979; Mahmood et al,
2014).
Hyperglycemia. Both pre-prandial and postprandial hyperglycemia have also been
linked to increased rates of atherosclerosis and cardiovascular disease (Bonora & Muggeo,
2001). Hyperglycemia may lead to these conditions due to an increase in blood viscosity.
Viscosity of the blood increases by 25% when blood glucose is increased to 400 mg∙dL-1 from
100 mg∙dL-1 (Cinar, Senyol & Duman, 2001). When the viscosity of the blood is increased, the
heart is required to work harder in order to maintain cardiac output. In most cases, heart rate will
increase due to a decreased left ventricular end diastolic volume as the result of decreased blood
flow. Blood flow decreases by 20% when blood glucose is raised from 100 mg∙dL-1 to 400
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mg∙dL-1 (Cinar, Senyol & Duman, 2001). This decrease in left ventricular end diastolic volume is
responsible for the decrease in stroke volume that follows. Blood pressure increases as a result of
increased resistance. Blood pressure increases by 25% to compensate for the increase in blood
viscosity in the aforementioned instance of a 300 mg∙dL-1 increase in blood sugar (Cinar, Senyol
& Duman, 2001). All of these effects increase the stress experienced by the heart and
collectively exacerbate symptoms of various cardiovascular diseases (Haffner & Cassells, 2003).
In short, the clinical data supports a connection between hyperglycemia and cardiovascular
disease (Haffner & Cassells, 2003; Haffner et al., 1998; Levitan et al., 2004). Though
hyperglycemia occurs in individuals with diabetes, the cardiovascular implications of abnormally
high blood glucose are not limited to those diabetics.
Hypoglycemia. At rest, the liver is constantly undergoing glycogenolysis in order to
maintain normal glucose levels. This process is accelerated at the onset of exercise as the
muscles continue to draw energy through catabolizing the available glucose in the bloodstream.
Hypoglycemia occurs when liver glycogen stores are depleted and there is no longer a source
from which to produce glycogen. The body continues to absorb glucose into tissue as long as the
requirement of energy exists and exercise is a condition that increases the metabolic demands of
the body. These demands must be met with the energy yielded from glucose through the process
of increased peripheral glucose uptake.
When an individual exercises, the blood sugar will experience an increase subsequently
followed by a decrease in the glucose availability for the duration of exercise. Hypoglycemia is
when blood glucose levels are well below values for healthy functioning and, just as
hyperglycemia, this possesses health implications (American Diabetes Association, 2018; Cryer,
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2007). Hypoglycemia is characterized as a blood glucose level that has fallen to ≤55-60 mg∙dL-1
(Cryer et al., 2009) and is often accompanied by hunger, confusion, dizziness, weakness,
seizures, coma and even hospitalization (Bonds et al., 2012). The brain possesses its own
glycogen stores within astrocytes in order to combat hypoglycemia (Brown & Ransom, 2007;
Suh et al., 2007). In severe cases an individual may turn unconscious (Musen et al., 2008) and
sustain decrements to mental processes (Cryer, 2007; Gonder-Frederick et al., 2009). The control
center of the body requires glucose as an energy source just as other tissue, and an inadequate
supply results in hypoglycemia of the brain leading to the aforementioned symptoms. This
condition may occur as the result of many preventable behaviors and states such as decreased
carbohydrate consumption, failure to eat and hyperinsulinemia due to taking an excess amount of
insulin as a diabetic. Hypoglycemia is especially dangerous in exercise conditions as well as in
individuals with diabetes mellitus as the hazard of seizing or fainting and entering a coma driven
by a lack of energy required for brain functioning is increased (Bohn et al., 2015). There are
quite a few antecedents to hypoglycemia that may warn an individual of impending
complications, such as hunger, irritability, blurry vision, sweating, and weakness and fatigue
(Bonds et al., 2012). The normoglycemic range is 70-99 mg∙dL-1 in a fasted state and below 140
mg∙dL-1 two hours postprandial (American Diabetes Association, 2001; Hill et al., 2011). It is
important that individuals with glucose management difficulties monitor blood glucose levels
and are take actions to prevent falling outside of the recommended normative blood glucose
levels in order to avoid the aforementioned symptoms and complications.
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Methods of Measurement
The Yellow Springs Instruments (YSI) Biochemistry Analyzer is capable of measuring
molecules that may be found in the blood such as lactate, ketones and glucose (Yellow Springs
Instruments, 2009). Validation studies (Lovrenčić et al., 2013; Robinson & Sharp, 2012;
Salacinski et al., 2014; Tack et al., 2012) often use the YSI Biochemistry Analyzer as the
reference method in order to determine the effectiveness of various blood analyzers. This
analyzer is quite effective due to its ability to report accurate and reliable values for a variety of
blood measures. The YSI has had its accuracy validated by glucose standards traceable to the
National Institute of Standards and Technology Standard Reference Material (Robinson & Sharp,
2012). One of the benefits of the YSI is that it does not require blood samples to be centrifuged
prior to being presented to the sipper. The YSI is capable of measuring values through both
whole and parted blood. Though the YSI is considered to be the gold standard, it suffers from a
few shortcomings. There are a myriad of technical weaknesses that are the direct result of human
error. The YSI uses a buffer solution that is used after a sample is processed in order to flush the
chamber in preparation for a new sample (Yellow Springs Instruments, 2009). This solution
flushes into a waste container that must be emptied once full. The buffer and the waste should
have a volume equal to a full container. For example, if the buffer is 75% full, then it should
follow that the waste is 25% full. This is because the volume from within the buffer container is
flushed into the waste container after each sample. Issues will ensue if the buffer is prepared
incorrectly or if the sum of the volume of buffer and waste exceeds a full container. The YSI will
continue to draw from the buffer solution as it is available. There are stainless steel shafts in each
container that terminate testing if either the calibration or buffer containers are empty or if the
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waste container is full (Yellow Springs Instruments, 2009). If the waste and buffer solution
container volumes are not equal to a full container, then there may be an extra termination than
necessary. This will halt testing until the respective containers are dealt with accordingly.
The YSI also requires the use of enzyme membranes as well as reagent and calibration
solutions. Improper installation of membranes or preparation of solutions will result in less than
accurate measures. One of the most prominent human-error complications that may halt data
collection is forcing a calibration to be made. When the YSI is ready to receive a sample, the
tester must press “Sample” and wait for the sipper to finish descending from the machine. Once
the sipper is completely descended, the tester may present the sample. It is imperative that the
tester keeps a steady hand for the entirety of the process until the sipper returns into the YSI. If
the sipper is bumped or deviated by the tester, then the YSI will retract the sipper and run a
calibration without testing the sample it has just received. This will halt data collection and will
require another blood draw from the participant if ample blood was not gathered for two
samples. This calibration will also start if the sipper descends for a sample yet no sample is
presented when it is ready. Calibration is required in order to uphold the accurate and reliable
results of the YSI Biochemistry Analyzer. The YSI may be configured to calibrate when desired
by the tester (Yellow Springs Instruments, 2009). This, however, poses an issue of data
collection time versus accuracy and reliability. For example, if the YSI is set to calibrate after
every five samples, then data collection for a study that requires multiple samples at multiple
data points will come to a halt numerous times. This results in the tester possibly limiting data
collection to one subject per session, which will ultimately extend the period of time required to
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complete data collection. Though the amount of calibrations taking place during a testing session
is a limiting factor, it is necessary that the calibrations are completed.
Aside from mechanical and user errors, the YSI also falls short as a practical method of
measuring blood glucose. Due to the price of the YSI Biochemistry Analyzers, they typically
will not be used in exercise physiology labs. The Biochemistry Analyzer is not an efficient field
testing method for the various blood variables that a tester may measure in combination with
exercise. The YSI is by no means intended to be a mobile device due to its need of electricity for
use, and the downtime needed to gather the sample for use with this machine also interferes with
exercise testing. It is also important to review the YSI Biochemistry Analyzer in terms of
practicality for diabetics. Glucose management and tracking are vital for the survival of
individuals with either type I or type II diabetes so is important that these individuals have a
cost-effective, reliable substitute for blood glucose measurement.
Glucometers. Handheld glucose monitors are small, mobile devices used for the
measurement of blood sugar. There are various brands and types of handheld glucose monitors
but the function of each is the same. These monitors report blood glucose through the use of
specialized strips that measure glucose through analyzing less than a drop of capillary blood. As
opposed to the YSI Biochemistry Analyzer, these monitors are portable, cost-effective, fast to
produce results and easy to operate. This technology is an exceptionally accessible option for
diabetic individuals who must manage their glucose levels manually throughout the day. The
efficacy of these monitors as reliable glucose observers has been determined by various studies
(Lovrenčić et al., 2013; Robinson & Sharp, 2012; Salacinski et al., 2014; Tack et al., 2012) in
which subject pools range from healthy to diabetic. These studies (Lovrenčić et al., 2013;
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Robinson & Sharp, 2012; Salacinski et al., 2014; Tack et al., 2012) examine the relationship
between blood glucose and various situations, such as exercise, and the effectiveness of the
handheld monitor in regards to reflecting those expected responses. Due to the importance of
accurate glucose measures for the diagnosis and management of diabetes, it is imperative that
these handhelds be both reliable and accurate regardless of the circumstance in which the subject
may be. Validation studies have used OGTTs, exercise, and fasting glucose levels in order to
examine monitor reliability and accuracy referenced against either the YSI Biochemistry
Analyzer or results gathered from accredited laboratory practices.
Validation studies are used as a means to determine whether the glucometers possess
criterion validity. Criterion validity is when the accuracy and reliability of the tested technology
are compared to a criterion method referred to as the reference. In the case of glucose monitors,
the monitor is compared against either the YSI or conventional laboratory methods as the
criterion.
Accuracy and reliability of glucometers. The results of the aforementioned studies were
varied. Many studies have made claims supporting the accuracy and reliability of handheld
glucose monitors while others deemed the monitors unfit for diagnosis and research purposes.
The StatStrip glucose meter produced by Nova Biomedical has been determined a reliable tool
for diabetes diagnosis. This particular monitor was produced for hospital use with technology
resistant to both hematocrit and drug-interference. The study conducted in order to determine the
efficacy of this product as a reliable diabetes diagnosis technology consisted of subjects
diagnosed with fasting or intermediate hyperglycemia (Lovrenčić et al., 2013). The subjects
arrived after an overnight fast and performed a two-hour OGTT in which measures were taken
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using venipuncture for the traditional laboratory glucose measurement procedure and capillary
blood for the Nova StatStrip monitors. Two StatStrip monitors using two separate batches of
StatStrip reagent strips were used at each time point immediately following the venous
collection.
The reference laboratory procedure and StatStrip monitor fasting plasma glucose
measures were highly correlated (r = 0.97) without a significant difference between the two
methods (Lovrenčić et al., 2013). The two-hour plasma glucose values upheld an excellent
correlation (r = 0.98); however, a significant difference was found between the two methods.
With the main purpose being to assess the diagnostic accuracy of modern handheld
glucose monitors for type II diabetes, the results of this study provide the first evidence that
point-of-care glucose meters, specifically the Nova StatStrip monitor, were comparable to the
validity of the reference laboratory procedures. Though most validation studies reference blood
glucose values of the monitors to the YSI Biochemistry Analyzer, it is important that these
monitors were also validated against other methods such as the laboratory procedures used in the
previous study. Due to the time consumption of remotely testing blood for glucose levels by way
of laboratory procedures, hospitals typically opt for the use of point-of-care handheld glucose
monitors for bedside treatment. Due to the need for effective bedside diabetes management it is
important that these monitors are not only fast but also valid. There are specific, international
standards for the accuracy of blood glucose monitors published by the International Organization
for Standardization (ISO) that hospitals must abide by. A study conducted in 2012 examined the
accuracy of six different handheld blood glucose monitors using the accuracy criteria listed by
the ISO 15197 published in 2003 (Robinson & Sharp, 2012). For this study, the YSI 2300 STAT
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PLUS was used as the reference for the comparison of the blood glucose monitoring handheld
test strips results. The methodology for the data collection was not specified, but it can be
assumed that there was no control over subject behavior due to the blood glucose concentrations
gathered over the course of the study ranging from 49 mg∙dL-1 to 444 mg∙dL-1.
Each of the 108 diabetic subjects received a finger prick from which all six handhelds
gathered capillary blood samples followed by YSI sample taken from the same finger stick
within 15 minutes of the first handheld sample being taken (Robinson & Sharp, 2012).
According to the criteria of the ISO 15197, five of the six handhelds used and referenced against
the YSI were up to accuracy standards. These results demonstrated the efficacy of handheld
glucose monitors as an effective method for bedside diabetes management (Robinson & Sharp,
2012). With these outcomes it can be inferred that handheld glucose monitors are effective for
diabetes management outside of the hospital environment, as well.
Another study using the ISO 15197:2003 standards as a means of accuracy determination
examined five commercially available monitors not used in the previous study. In this study 453
subjects with type I or type II diabetes arrived to the facility in a fasted state and performed the
sample collection just as they would at home. This was repeated for three of the five monitors,
each of which was randomly assigned to each subject. A healthcare professional gathered
capillary blood for the YSI 2300 STAT PLUS before and after each self-test performed by the
subject (Tack et al., 2012). Regression analyses were performed for each blood glucose
monitoring system against the YSI, resulting very high correlations for each system (r = 0.97 to
0.99). Three of the five handheld glucose monitors were found to be highly accurate in
comparison to the YSI 2300 STAT PLUS (Tack et al., 2013). The results of this study provide
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data demonstrating that the commercially available monitors meant for use by type I and II
diabetics are valid for self-monitoring when used by the diabetics themselves. Though there are
multiple studies showing the accuracy and validity of handheld glucose monitors for both
hospital and home use, there are conflicting data. In particular, some studies have found that
these monitors should only be used for patient management rather than for hospital and research
purposes. A study using 15 moderately to highly active men and women attempted to precisely
measure the validity and reliability of handheld glucose meters for biomedical research
(Salacinski et al., 2014). This validation study referenced the values of the handheld glucose
monitor against the YSI 2300 STAT PLUS, using a fasted OGTT as the protocol. Measurements
were taken prior to glucose administration and then at 10, 20, 30, 60 and 90 minutes
postprandial. The ISO necessitates that handheld glucose monitors be within 20% of the
reference value if glucose concentrations are above 76 mg∙dL-1; however, the results of this study
found that only 82% of the total number of glucometer readings fell within this criteria
(Salacinski et al., 2014). Glucometer technology is progressing in order to improve accuracy, and
due to the conflicting results among the currently available validity and reliability studies, it is
important that more research is conducted in order to properly determine the efficacy of
glucometer usage.

The oral glucose tolerance test. Testing glycemia is an essential step in the diagnosis of
diabetes in patients. Tests used for diagnosis have been established over the years, such as
random and fasting blood glucose, HbA1c and the OGTT. Fasting and random glucose measures
are simply when glucose is measured either in a fasted state or at a random moment during the
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day. HbA1c is the amount of hemoglobin in the blood that has become glycated (i.e. joined with
glucose). This value allows for the estimation of average glucose over the previous months
(Rohlfing et al., 2002). The OGTT has become the gold standard for diabetes diagnosis due to its
use in a multitude of studies (Barr et al., 2002). The OGTT is a dynamic test due to its ability to
allow the examiner to observe both fasting blood glucose and the way a patient’s body processes
glucose following ingestion. Unlike fasting blood glucose in which the subject refrains from
eating and blood glucose is measured, the OGTT expresses postprandial blood glucose levels as
well. Postprandial blood glucose is important because it allows for a look at how efficient the
patient’s systems are at storing and utilizing the glucose that has been consumed.
Glucose intolerance, or an elevated glucose concentration, is a sign of insulin resistance
which may be used to diagnose diabetes or a pre-diabetic state in a patient. The normoglycemic
range should be below 140 mg∙dL-1 two hours after glucose consumption, which means that a
healthy body is storing and using the glucose effectively after a meal (American Diabetes
Association, 2018; Hill et al., 2011). Glucose will increase following a meal due to the
carbohydrate content of the food and then continue to decrease to homeostatic values. In healthy
individuals, peptides responsible for glucose homeostasis within the gastrointestinal system are
released and these peptides facilitate the release of insulin. Diabetics tend to be insulin resistant,
which leads to postprandial blood glucose concentrations above healthy levels well after
consumption.
As fasting glucose tests determine an individual’s insulin resistance by observing where
blood glucose is after an extended period of not eating, OGTTs aid in the detection of insulin
resistance in the form of blood glucose concentrations following meal consumption. OGTTs
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consist of the subject consuming carbohydrate, typically a 75 g glucose solution, after fasting.
Blood glucose is measured multiple times over a period of one to three hours, with two hours
being the norm due to the ADAs classification of normoglycemia being >140 mg∙dL-1 two hours
postprandial. The subject’s fasting glucose is to be taken prior to ingestion of the glucose and is
used as the baseline measure for the test. The results of this test have implications for exercise.
Hyperglycemia affects the viscosity of the blood, which leads to an increased stroke volume in
order to combat the decrease of blood returned to the heart. Individuals with hyperglycemia
typically have a higher blood pressure than normal, which poses an issue in the case of resistance
training and exercises that are responsible for increasing blood pressure in healthy individuals.
Many validation studies opt for the use of OGTTs because they allow for the examination of
handheld glucose monitor values against the reference method values over the course of a couple
hours. This gives the examiner a chance to observe the accuracy of the handheld glucose meter
throughout the course of the insulin response.
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